You are here: All Products  > AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC

AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products